Company News »

Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment

Business Wire
Share on StockTwits
Published on

Cytori Therapeutics, Inc. (NASDAQ:CYTX) has received notification from the FDA that Cytori has provided additional information sufficient to support continuation of enrollment in its ATHENA cardiovascular trials. The FDA has agreed that the submitted data and protocol amendments support the fact that there are no subject protection concerns that preclude continuation of the trials.

The ATHENA trials have enrolled a total of 31 patients thus far but enrollment was stopped last May by the company based on meeting the trials’ internal stopping rules related to potential cerebrovascular events affecting both cell and placebo treated patients.

Based on consultation with the FDA, Cytori initiated a thorough safety review consisting of evaluating each adverse event in all of its previous and ongoing cardiovascular trials and conducted additional testing of its product and cellular output. In addition, Cytori implemented several protocol changes to enhance the safety of the trial procedures for patients. The FDA response to Cytori’s submission was received on October 22, 2014.

“Cytori is first and foremost focused on patient safety in all its endeavors, and we are pleased to have successfully navigated this issue. Such issues are not uncommon in development programs involving novel technology for a severely ill population,” said Dr. Marc Hedrick, President and Chief Executive Officer of Cytori. “Currently, we are assessing what this delay means for this particular trial and will provide an updated plan on our forthcoming quarterly investor call.”

About Cytori Therapeutics, Inc.

Cytori Therapeutics, Inc. is developing cell therapies based on autologous ADRCs to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution(R) system product family. For more information, visit

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our belief in the safety of the Celution(R) System cell output, are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include our pressing need to raise additional capital, clinical, pre-clinical and regulatory uncertainties, the quality of data supporting execution of ATHENA trials, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.

Share on StockTwits